Workflow
马来酸依那普利片
icon
Search documents
百利天恒子公司药品挂网价遭疑,70倍价差背后的风险几何?
Xin Lang Zheng Quan· 2025-09-26 09:01
一瓶口服溶液挂网价558元,而同通用名普通片剂价格仅约8元,近70倍的价差背后,是亟待厘清的研发 成本,还是隐藏不当营销的灰色空间? 云南省医疗保障局的一纸问询函,将上市公司百利天恒的全资子公司——四川百利药业推至聚光灯下。 9月24日,云南医保局就百利药业生产的马来酸依那普利口服溶液挂网价格高达558元发出公开问询,要 求其说明价格构成、销售利润、价差合理性及是否存在不当营销等四项问题。 这并不是该产品首次因价格问题引发关注。就在十天前的9月15日,上海阳光医药采购网已发布通知, 暂停包括该口服溶液在内的15个品规药品采购资格。接连被两地监管机构重点关注,折射出当前药品价 格监管的高压态势。 高价的质疑:剂型差异能否支撑70倍价差? 马来酸依那普利是一种经典的血管紧张素转化酶抑制剂(ACEI),广泛用于治疗原发性高血压、肾性 高血压和充血性心力衰竭。该药的主流剂型为片剂,已多次被纳入国家集采,价格大幅下降。 以扬子江药业生产的马来酸依那普利片为例,经过集采两轮降价,从每盒19.15元降至5.66元,降幅达 70.4%。相比之下,百利药业生产的口服溶液剂型挂网价高达558元,与集采片剂形成近70倍的价差。 结 ...
70倍价差!四川百利药业因558元高价口服溶液遭医保局问询,系百利天恒全资子公司
Shen Zhen Shang Bao· 2025-09-25 14:55
9月24日,云南省医保局向四川百利药业有限责任公司(简称"百利药业")发出公开问询函。 一、请详细说明你公司马来酸依那普利口服溶液的出厂价格、终端价格,以及研发投入、生产制造、期间费用等各项价格构成情况。 不同于已经进入集采的片剂,马来酸依那普利口服溶液目前还较为稀缺,根据国家药监局数据查询系统的信息,仅有两家生产企业。相较于片剂,口服溶 液的研发和生产门槛更高,需要解决药物的溶解度、稳定性、口感、防腐等一系列技术问题。 二、请详细说明你公司马来酸依那普利口服溶液近5年各年度销售量、销售金额,以及你公司作为生产研发企业的实际利润等情况。 三、请详细说明你公司马来酸依那普利口服溶液出厂价格和终端价格之间价差的合理性、必要性,以及终端价格构成中所含全部销售费用的资金支出去向 等情况。 资料显示,马来酸依那普利是一种血管紧张素转化酶抑制剂(ACEI),呈白色至灰白色结晶性粉末,临床主要用于治疗各期原发性高血压、肾性高血压 及充血性心力衰竭,并能改善症状性心衰患者的生存率及降低住院风险。 公开函件显示,百利药业生产的马来酸依那普利口服溶液挂网价格高达558元,与同通用名不同剂型(片剂,单价8元左右)存在近70倍价差。 ...
国药现代(600420.SH):马来酸依那普利片通过仿制药一致性评价
Ge Long Hui A P P· 2025-09-17 08:26
格隆汇9月17日丨国药现代(600420.SH)公布,公司收到国家药品监督管理局核准签发的《药品补充申请 批准通知书》,批准马来酸依那普利片(5mg)通过仿制药质量和疗效一致性评价。马来酸依那普利片 为一种血管紧张素转移酶抑制药,主要用于治疗原发性高血压、肾血管性高血压及症状性心力衰竭等病 症。 ...
国药现代(600420.SH):马来酸依那普利片通过一致性评价
智通财经网· 2025-09-17 08:25
智通财经APP讯,国药现代(600420.SH)公告,公司收到国家药品监督管理局核准签发的《药品补充申 请批准通知书》,批准马来酸依那普利片(5mg)通过仿制药质量和疗效一致性评价。马来酸依那普利片 为一种血管紧张素转移酶抑制药,主要用于治疗原发性高血压、肾血管性高血压及症状性心力衰竭等病 症。 ...
国药现代:马来酸依那普利片通过一致性评价
Zhi Tong Cai Jing· 2025-09-17 08:25
国药现代(600420)(600420.SH)公告,公司收到国家药品监督管理局核准签发的《药品补充申请批准 通知书》,批准马来酸依那普利片(5mg)通过仿制药质量和疗效一致性评价。马来酸依那普利片为一种 血管紧张素转移酶抑制药,主要用于治疗原发性高血压、肾血管性高血压及症状性心力衰竭等病症。 ...
国药现代:马来酸依那普利片通过仿制药一致性评价
Ge Long Hui· 2025-09-17 08:22
格隆汇9月17日丨国药现代(600420.SH)公布,公司收到国家药品监督管理局核准签发的《药品补充申请 批准通知书》,批准马来酸依那普利片(5mg)通过仿制药质量和疗效一致性评价。马来酸依那普利片 为一种血管紧张素转移酶抑制药,主要用于治疗原发性高血压、肾血管性高血压及症状性心力衰竭等病 症。 ...
千金药业: 天健会计师事务所(特殊普通合伙)关于株洲千金药业股份有限公司发行股份及支付现金购买资产暨关联交易申请的审核问询函之问询问题中有关财务事项的说明(修订稿)
Zheng Quan Zhi Xing· 2025-07-04 16:34
Company Overview - Zhuzhou Qianjin Pharmaceutical Co., Ltd. primarily engages in the research, production, and sales of chemical synthetic raw materials and solid preparations, with key products including Valsartan capsules and other medications [3][5] - Qianjin Xiangjiang Pharmaceutical's nine centralized procurement varieties have seen sales growth exceeding 20% year-on-year, while Qianjin Xieli Pharmaceutical's product, Benazepril, has experienced over 30% sales growth [3][5] Revenue Analysis - The company has reported significant revenue from centralized procurement, with the revenue from centralized procurement increasing substantially over the reporting period [9][10] - For Qianjin Xiangjiang Pharmaceutical, the revenue from centralized procurement accounted for 57.09% in 2024, up from 7.50% in 2020, indicating a strong shift towards centralized procurement sales [9][10] - The average selling price for centralized procurement has decreased from 7.66 to 6.61, while the non-centralized procurement price has also seen a decline from 25.99 to 17.50 [9][10] Market Position and Competitive Landscape - The market for hypertension medications is projected to grow, with the number of hypertension patients in China expected to reach 400 million by 2030, driving demand for products like Valsartan [7][8] - Qianjin Xiangjiang holds approximately 3% market share in the Valsartan segment, while its market share in other products varies, indicating a competitive landscape with several key players [7][8] - The company benefits from a self-operated team and strong brand recognition, which enhances its market position against competitors [7][8] Product Development and Pipeline - The company has several products undergoing research and development, with a focus on expanding its portfolio in response to market needs [6][8] - The market for liver protection drugs, such as Silymarin, is expected to grow significantly, with Qianjin Xieli's market share projected to reach 40% by 2030 [8] Cost and Expense Management - The company has optimized its production processes, which is expected to enhance its cost management and pricing strategies in future centralized procurement rounds [8][9] - The gross profit margin for centralized procurement products has improved, reflecting better cost control and pricing strategies [9][10]
昂利康:研发高投入压低短期利润 创新药布局蓄力长期增长
Zheng Quan Ri Bao Wang· 2025-04-27 13:41
Core Viewpoint - Zhejiang Anglikang Pharmaceutical Co., Ltd. reported a revenue of 1.538 billion yuan and a net profit of 80.3345 million yuan for 2024, reflecting a year-on-year decline of 41.94% in net profit primarily due to increased R&D expenditures [1] Group 1: Financial Performance - The company achieved a revenue of 1.538 billion yuan in 2024 [1] - The net profit attributable to shareholders was 80.3345 million yuan, down 41.94% year-on-year [1] - R&D expenses reached 231 million yuan, an increase of 33.74% year-on-year, accounting for 14.99% of total revenue [1] Group 2: R&D and Innovation - Anglikang secured 19 new invention patents in 2024 and participated in drafting national standards for pharmaceutical excipients [2] - The company received drug registration certificates for six products, including phosphate sitagliptin tablets and sacubitril valsartan sodium tablets [2] - Anglikang is accelerating its transformation towards innovative drugs, collaborating with Shanghai Qinhuli Biotechnology Co., Ltd. on the development of ALK-N001/QHL-1618 [2] Group 3: Industry Upgrades and Pet Medicine - The company is advancing technology upgrades with a focus on "raw materials + formulations" integration, optimizing processes to reduce energy consumption [3] - Significant progress was made in the pet medicine sector, with several products receiving GMP certification and approval numbers [3] - Anglikang is developing innovative vaccines for pets in collaboration with China Agricultural University, and a chronic pain rehabilitation software project has entered the registration application phase [3]